Three-Pronged attack on rare, aggressive blood cancer
NCT ID NCT05388006
Summary
This study is testing a combination of three drugs—acalabrutinib, venetoclax, and durvalumab—to see if they can help control a rare and aggressive cancer called Richter transformation. Richter transformation occurs when a slower-growing blood cancer (CLL) suddenly changes into a fast-growing lymphoma. The trial aims to see if this three-drug approach can stop the cancer from progressing and improve survival for the 27 patients enrolled.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mayo Clinic in Rochester
RECRUITINGRochester, Minnesota, 55905, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Stanford Cancer Institute Palo Alto
NOT_YET_RECRUITINGPalo Alto, California, 94304, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Washington University School of Medicine
WITHDRAWNSt Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.